Skip to content
This content is from our sponsor. The sponsor has sole editorial control.

MED-EL - A Leader in Innovative Hearing Technology

As the industry's technology leader in implantable hearing solutions, MED-EL products are the result of more than 30 years of focused research and a commitment by its founders to fostering a company culture of excellence.

MED-EL has a strong tradition of advancing the technological and scientific foundation in the field of hearing implants. The company's strong and consistent focus on research and development will continue to fuel the pipeline of new ideas and innovations. Their broad portfolio of products ensures that they can provide a hearing implant solution to fit each candidate's unique hearing loss.

MED-EL's development of the MAESTRO cochlear implant system has given a superior medical option to individuals with severe to profound sensorineural hearing loss. For individuals with this type of hearing loss, hearing aids provide little or no benefit. The system contains features optimized for the appreciation of music and for listening in challenging situations.

MAESTRO consists of both an internal cochlear implant and an externally worn audio processor. MED-EL offers processors that can be worn behind the ear (BTE) or off the ear. No matter whether the single-unit RONDO or behind-the-ear OPUS 2 is the right option for you, rest assured that superior hearing is already built in. Both processors feature exclusive MED-EL technologies for best hearing performance.


World's First Single-Unit Processor

The World's First CI Single-Unit Processor

Compact and Fully Integrated

The control-unit, battery pack, and coil are combined into one single-unit processor design. With no cable and fewer parts, users benefit from enhanced durability. The fully integrated design makes RONDO simple to wear.

Convenient and Off the Ear

RONDO disappears easily under longer hair. Because the ear is free, RONDO is especially comfortable for individuals who regularly wear glasses of any kind.

Proven Performance for Everyday Life

RONDO is based on the proven OPUS audio processor platform. It features the same signature technologies, Automatic Sound Management and FineHearing Technology, which provide proven superior hearing performance.1,2


  • FineHearing®1 Technology, featuring the fine details of sound, provides an even more detailed hearing experience.
  • Automatic Sound Management ensures optimal hearing in changing and challenging listening situations, all without requiring the user to make program adjustments.
  • The small, easy-to-use FineTuner remote control.

Industry Firsts

MED-EL International Timeline


Ingeborg and Erwin Hochmair begin development of cochlear implants at the Technical University of Vienna.


The world's first hybrid multi-channel cochlear implant, developed by Ingeborg and Erwin Hochmair, is implanted.


MED-EL is founded in Innsbruck, Austria.

COMFORT, MED-EL's first cochlear implant system, is introduced. The electrode uses wave-shaped wires to maximize structure preservation in the cochlea.


The COM-3 becomes part of the COMFORT system. It is the world's first behind-the-ear (BTE) audio processor.


The CIS-PRO pocket audio processor and COMBI 40 cochlear implant are introduced. They are the world's first to provide 8-channel high-rate stimulation with the CIS coding strategy.

The world's first electrode designed for Complete Cochlear Coverage is introduced for the COMBI 40.


The CIS LINK System is introduced.


The CIS-PRO+ audio processor and COMBI 40+ cochlear implant are introduced. They improve upon the CIS-PRO and COMBI 40 by providing 12 stimulation channels.

The Standard electrode is introduced. This is the first MED-EL electrode to use 12 electrical channels.

The world's first bilateral cochlear implantation uses MED-EL implants and audio processors.


The TEMPO+ BTE audio processor is introduced. It is the first BTE audio processor to use the CIS+ coding strategy.

First BTE to provide a wearing option for young children: the BabyBTE.

In Europe, the world's first use of combined electric and acoustic stimulation (EAS) in a cochlear implant recipient uses a MED-EL implant and audio processor.


VIBRANT MED-EL is founded.

The Vibrant Soundbridge is introduced. It is the world's first middle-ear implant, designed for use in cases of conductive3 or sensorineural hearing loss.


The PULSAR ceramic cochlear implant is introduced.

The FLEX EAS3 electrode (now known as the FLEX24) is introduced. Its unique FLEX-Tip continues MED-EL's philosophy of maximizing structure preservation.


The MED-EL EAS System is introduced with the DUET EAS Audio Processor3. It is the first cochlear implant system designed for combined electric and acoustic stimulation.


The SONATA cochlear implant is introduced. It is MED-EL's first implant with a titanium housing.

The OPUS 2 is introduced. It is the world's first switchless audio processor.

The FLEXSOFT electrode4 is introduced. It is the world's longest cochlear implant electrode, and reaffirms MED-EL's commitment to Complete Cochlear Coverage.


The DUET 2 Audio Processor3 improves upon the DUET EAS.

The Amadé Audio Processor is introduced for use with the Vibrant Soundbridge.


The MED-EL CONCERT cochlear implant is introduced. It is the world's thinnest titanium implant.

The MAESTRO System Software 4.0 introduces new FineStructure coding strategies.


The FLEX28 electrode is introduced. It features FLEX-Tip technology and is designed for use in 96% of all typical cochlear anatomies.


The OPUS 2XS is introduced. It is the world's smallest CI audio processor.

The BONEBRIDGE is introduced. It is the world's first transcutaneous bone conduction implant4.


The RONDO is introduced.

It is the world's first single-unit processor for cochlear implants.

MED-EL receives FDA approval to be the first and only manufacturer with cochlear implants available for 1.5T MRI scans without magnet removal in the USA.

  1. Fine Structure coding strategies are not indicated for use by prelingual children in the USA.
  2. Haumann et al. (2010), ORL 2010;72:312-318.
  3. This indication is currently under investigation in the USA.
  4. This device is not currently approved for use in the USA.

© 2014 MED-EL

WebMD does not endorse any specific product, service, or treatment.